December 12, 2025

Contracts signed for Heidelberg-Mannheim hospital network

Contracts signed for Heidelberg-Mannheim hospital network

It’s now official: the alliance between the two university hospitals in Heidelberg and Mannheim can start as planned on January 1 and begin its work. Press release from the Baden-Württemberg Ministry of Science, Research, and the Arts.

Full Text in German below.


Verträge zum Klinikverbund Heidelberg-Mannheim unterzeichnet

Nun ist es offiziell: Der Verbund zwischen den beiden Universitätsklinika Heidelberg und Mannheim kann zum 1. Januar wie geplant starten und seine Arbeit beginnen. Pressemitteilung des Ministeriums für Wissenschaft, Forschung und Kunst Baden-Württemberg

Die Verträge sind gestern, 8. Dezember, in Stuttgart im Ministerium für Wissenschaft, Forschung und Kunst (MWK) unterschrieben worden. Zu den Unterzeichnerinnen und Unterzeichnern gehörten neben den Leitungen der beiden Klinika Wissenschaftsministerin Petra Olschowski, der Mannheimer Oberbürgermeister Christian Specht und die Rektorin der Universität Heidelberg, Professorin Frauke Melchior.

„Sehr gute Nachricht für das Land Baden-Württemberg“

Die Universitätsklinik Heidelberg übernimmt damit knapp 90 Prozent der Anteile der Universitätsklinik Mannheim. „Das ist eine sehr gute Nachricht für die beiden Klinika und für das Land Baden-Württemberg“, sagte Wissenschaftsministerin Olschowski. „Mit dem Klinikverbund stärken wir weiter die nationale und internationale Sichtbarkeit unserer Spitzenmedizin und verbessern darüber hinaus die Lehre, Forschung und Versorgung der Patientinnen und Patienten im Land.“

Am 12. Januar wird es noch eine feierliche Auftaktveranstaltung zum Klinikverbund in Mannheim und Heidelberg geben.

Weitere Informationen im Internet

Diese Pressemitteilung auf der Website des MWK

Our latest News

discover more
Tailor-Made Fertilization

Tailor-Made Fertilization

Excessive fertilization in agriculture weakens crops, threatens drinking water quality, and harms the soil. Researchers at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB are now developing an alternative fertilizer that is fully biodegradable, supplies plants exclusively with the nutrients they need, and prevents over-fertilization. More information in German below: Jahr für Jahr werden […]

Two German Cancer Awards for Researchers at Heidelberg University’s Faculty of Medicine

Two German Cancer Awards for Researchers at Heidelberg University’s Faculty of Medicine

Professor Dr. Jessica Hassel, Faculty of Medicine Heidelberg at Heidelberg University and Head of the Skin Cancer Center at Heidelberg University Hospital and the National Center for Tumor Diseases (NCT) Heidelberg, has been awarded in the category “Clinical Research.” Professor Dr. Dr. Felix Sahm, also from the Faculty of Medicine Heidelberg, Department of Neuropathology at […]

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Paris, March 31, 2026. The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and older with a body weight of at least 40 kg. The medicine is to […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp